Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

547.36 -0.38 (-0.07%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
2 Beaten-Down Stocks to Buy and Hold
Via The Motley Fool
Topics Death
REGENERON PHARMACEUTICALS (NASDAQ:REGN) - A Potential Undervalued Biotech Stock
REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector. 
Via Chartmill
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial. 
Via Benzinga
Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps
While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory... 
Via Stocktwits
Topics Death
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For July 01
Via Benzinga
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead. 
Via MarketBeat
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
1 Profitable Stock for Long-Term Investors and 2 to Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns. 
Via Benzinga
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results. 
Via Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation. 
Via Stocktwits
Topics Supply Chain
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said. 
Via Stocktwits
Topics Death
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching. 
Via The Motley Fool
Topics Stocks
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
From 23andMe, Inc.
Via GlobeNewswire
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you. 
Via The Motley Fool
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Via The Motley Fool
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity. 
Via Benzinga
Regeneron Pharma Shares Rise Over 3% After Key Signal
A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%. 
Via Benzinga
Which S&P500 stocks are moving on Monday?
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.